- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04634877
Studio di Pembrolizumab (MK-3475) in combinazione con chemioterapia adiuvante con o senza radioterapia in partecipanti con carcinoma endometriale di nuova diagnosi dopo intervento chirurgico con intento curativo (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Uno studio di fase 3, randomizzato, in doppio cieco su pembrolizumab versus placebo in combinazione con chemioterapia adiuvante con o senza radioterapia per il trattamento del carcinoma endometriale ad alto rischio di nuova diagnosi dopo intervento chirurgico con intento curativo (KEYNOTE-B21 / ENGOT-en11 / GOG- 3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Buenos Aires, Argentina, C1012AAR
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
-
Buenos Aires, Argentina, C1118AAT
- Hospital Aleman ( Site 1001)
-
La Rioja, Argentina, F5300COE
- Centro Oncologico Riojano Integral ( Site 1007)
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentina, B1884BBF
- Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
-
CABA, Buenos Aires, Argentina, C1012AAR
- IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
-
CABA, Buenos Aires, Argentina, C1431FWO
- CEMIC ( Site 1009)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB
- Hospital Britanico de Buenos Aires ( Site 1002)
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Instituto de Oncologia de Rosario ( Site 1004)
-
-
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medizinische Universitat Graz ( Site 2004)
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Medizinische Universitaet Innsbruck ( Site 2001)
-
-
-
-
-
Liège, Belgio, 4000
- CHC - Groupe Sante ( Site 2041)
-
Liège, Belgio, 4000
- CHU Liege Sart-Tilman ( Site 2044)
-
-
Bruxelles-Capitale, Region de
-
Brussels, Bruxelles-Capitale, Region de, Belgio, 1200
- Saint-Luc UCL ( Site 2042)
-
-
Hainaut
-
Mons, Hainaut, Belgio, 7000
- C.I.U. Hopital Ambroise Pare ( Site 2039)
-
-
Liege
-
Verviers, Liege, Belgio, 4800
- CHR Verviers ( Site 2035)
-
-
Oost-Vlaanderen
-
Aalst, Oost-Vlaanderen, Belgio, 9300
- AZORG Campus Aalst-Moorselbaan ( Site 2038)
-
Ghent, Oost-Vlaanderen, Belgio, 9000
- AZ Maria Middelares Gent ( Site 2032)
-
Ghent, Oost-Vlaanderen, Belgio, 9000
- Universitair Ziekenhuis Gent ( Site 2037)
-
Sint-Niklaas, Oost-Vlaanderen, Belgio, 9100
- AZ Nikolaas ( Site 2031)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgio, 3000
- UZ Leuven ( Site 2040)
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, Belgio, 8500
- AZ Groeninge ( Site 2036)
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 3007)
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre ( Site 3003)
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0C1
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre ( Site 3005)
-
Québec, Quebec, Canada, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3002)
-
-
-
-
-
Olomouc, Cechia, 77900
- Fakultni nemocnice Olomouc ( Site 2392)
-
-
Brno-mesto
-
Brno, Brno-mesto, Cechia, 62500
- Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 2394)
-
-
Praha 10
-
Prague, Praha 10, Cechia, 100 34
- Fakultni nemocnice Kralovske Vinohrady ( Site 2393)
-
-
Praha 2
-
Prague, Praha 2, Cechia, 128 08
- Vseobecna fakultni nemocnice v Praze ( Site 2391)
-
-
-
-
Araucania
-
Temuco, Araucania, Chile, 4800827
- Centro Investigación del Cáncer James Lind ( Site 1061)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- Fundacion Arturo Lopez Perez FALP ( Site 1062)
-
Santiago, Region M. de Santiago, Chile, 8330032
- Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)
-
Santiago, Region M. de Santiago, Chile, 8420383
- Bradfordhill-Clinical Area ( Site 1070)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Oncocentro ( Site 1065)
-
-
-
-
Anhui
-
Hefei, Anhui, Cina, 230001
- Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 4034)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100036
- Beijing Cancer Hospital ( Site 4048)
-
Beijing, Beijing Municipality, Cina, 100730
- Peking Union Medical College Hospital ( Site 4036)
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Cina, 400030
- Chongqing Cancer Hospital ( Site 4040)
-
-
Fujian
-
Xiamen, Fujian, Cina, 361003
- The First Affiliated Hospital of Xiamen University ( Site 4060)
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510080
- The First Affiliated Hospital ( Site 4043)
-
-
Guangxi
-
Nanning, Guangxi, Cina, 530221
- Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)
-
-
Heilongjiang
-
Harbin, Heilongjiang, Cina, 150081
- Harbin Medical University Cancer Hospital ( Site 4033)
-
-
Hubei
-
Wuhan, Hubei, Cina, 430079
- Hubei Cancer Hospital ( Site 4059)
-
-
Hunan
-
Changsha, Hunan, Cina, 410006
- Hunan Cancer Hospital ( Site 4050)
-
Changsha, Hunan, Cina, 410008
- Xiangya Hospital Central South University ( Site 4035)
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210008
- Nanjing Drum Tower Hospital ( Site 4037)
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 530021
- Jiangxi Maternal and Child Health Hospital ( Site 4051)
-
-
Jilin
-
Changchun, Jilin, Cina, 130000
- The First Hospital of Jilin University ( Site 4057)
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710061
- The First Affiliated Hospital of Xi an Jiaotong University ( Site 4045)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200090
- Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)
-
Shanghai, Shanghai Municipality, Cina, 200127
- Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)
-
Shanghai, Shanghai Municipality, Cina, 201204
- Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- Sichuan Cancer Hospital. ( Site 4039)
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300000
- Tianjin Medical University Cancer Institute & Hospital ( Site 4054)
-
-
Yunnan
-
Kunming, Yunnan, Cina, 650107
- Yunnan Province Cancer Hospital-Gynecology Department ( Site 4055)
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310003
- The First Affiliated Hospital, Zhejiang University-Gynecology ( Site 4002)
-
Hangzhou, Zhejiang, Cina, 310006
- Women s Hospital School of Medicine Zhejiang University ( Site 4032)
-
Wenzhou, Zhejiang, Cina, 325000
- The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 1096)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 111511
- Instituto Nacional de Cancerología E.S.E ( Site 1094)
-
-
Departamento de Nariño
-
Pasto, Departamento de Nariño, Colombia, 520002
- Instituto Cancerologico de Nariño S.A.S. ( Site 1092)
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Fundación Valle del Lili ( Site 1093)
-
-
-
-
-
Seoul, Corea del Sud, 03722
- Severance Hospital Yonsei University Health System ( Site 4062)
-
Seoul, Corea del Sud, 05505
- Asan Medical Center ( Site 4061)
-
Seoul, Corea del Sud, 06351
- Samsung Medical Center ( Site 4064)
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Corea del Sud, 10408
- National Cancer Center ( Site 4065)
-
Seongnam-si, Kyonggi-do, Corea del Sud, 13620
- Seoul National University Bundang Hospital ( Site 4063)
-
-
-
-
Capital Region
-
Copehagen, Capital Region, Danimarca, 2100
- Rigshospitalet University Hospital ( Site 2515)
-
Herlev, Capital Region, Danimarca, 2730
- Herlev Hospital ( Site 2514)
-
-
North Denmark
-
Aalborg, North Denmark, Danimarca, 9100
- Aalborg Universitetshospital ( Site 2511)
-
-
Region Sjælland
-
Roskilde, Region Sjælland, Danimarca, 4000
- Roskilde Sygehus ( Site 2513)
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Danimarca, 5000
- Odense Universitetshospital ( Site 2512)
-
-
-
-
Northern Savonia
-
Kuopio, Northern Savonia, Finlandia, 70210
- Kuopio University Hospital ( Site 2543)
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finlandia, 33520
- Tampere University Hospital ( Site 2541)
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlandia, 20520
- Turku University Hospital ( Site 2542)
-
-
-
-
Ain
-
Vandœuvre-lès-Nancy, Ain, Francia, 54519
- Institut De Cancerologie De Lorraine ( Site 2072)
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Francia, 06189
- Centre Antoine Lacassagne ( Site 2073)
-
-
Calvados
-
Caen, Calvados, Francia, 14076
- Centre Francois Baclesse ( Site 2062)
-
-
Cotes-d Armor
-
Plérin, Cotes-d Armor, Francia, 22190
- Hôpital Privé Des Côtes d'Armor ( Site 2063)
-
-
Doubs
-
Besançon, Doubs, Francia, 25000
- CHU Besancon - Hopital Jean Minjoz ( Site 2068)
-
-
Gironde
-
Bordeaux, Gironde, Francia, 33076
- Institut Bergonie ( Site 2067)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Francia, 31059
- Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)
-
-
Herault
-
Montpellier, Herault, Francia, 34298
- Institut Regional du Cancer de Montpellier - ICM ( Site 2069)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Francia, 44277
- Hopital prive du Confluent ( Site 2061)
-
-
Rhone
-
Pierre-Bénite, Rhone, Francia, 69310
- Centre Hospitalier Lyon Sud ( Site 2064)
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francia, 75014
- Hopital Cochin ( Site 2070)
-
Villejuif, Île-de-France Region, Francia, 94805
- Gustave Roussy ( Site 2071)
-
-
-
-
Baden-Wurttemberg
-
Heilbronn, Baden-Wurttemberg, Germania, 74078
- SLK-Kliniken Heilbronn GmbH ( Site 2116)
-
Ludwigsburg, Baden-Wurttemberg, Germania, 71640
- Klinikum Ludwigsburg ( Site 2111)
-
Tübingen, Baden-Wurttemberg, Germania, 72076
- Universitaetsklinikum Tuebingen ( Site 2113)
-
-
Lower Saxony
-
Hanover, Lower Saxony, Germania, 30625
- Medizinische Hochschule Hannover-Department of Obstetrics and Gynecology ( Site 2109)
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Germania, 53127
- Universitätsklinikum Bonn-Gynaecological oncology ( Site 2103)
-
Essen, North Rhine-Westphalia, Germania, 45136
- Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2105)
-
-
Saxony
-
Dresden, Saxony, Germania, 01307
- Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2104)
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Germania, 23538
- Universitätsklinikum Schleswig-Holstein ( Site 2101)
-
-
-
-
-
Fukuoka, Giappone, 811-1395
- National Hospital Organization Kyushu Cancer Center ( Site 4193)
-
Niigata, Giappone, 951-8566
- Niigata Cancer Center Hospital ( Site 4185)
-
Osaka, Giappone, 541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 4188)
-
Tokyo, Giappone, 160-8582
- Keio University Hospital ( Site 4191)
-
Tokyo, Giappone, 135-8550
- Cancer Institute Hospital of JFCR ( Site 4196)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Aichi Cancer Center ( Site 4190)
-
-
Chiba
-
Kashiwa, Chiba, Giappone, 277-8577
- National Cancer Center Hospital East ( Site 4197)
-
-
Ehime
-
Matsuyama, Ehime, Giappone, 791-0280
- National Hospital Organization Shikoku Cancer Center ( Site 4181)
-
Tōon, Ehime, Giappone, 791-0295
- Ehime University Hospital ( Site 4187)
-
-
Fukuoka
-
Kurume, Fukuoka, Giappone, 830-0011
- Kurume University Hospital ( Site 4186)
-
-
Gunma
-
Ōta, Gunma, Giappone, 373-8550
- Gunma Prefectural Cancer Center ( Site 4183)
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 060-8648
- Hokkaido University Hospital ( Site 4194)
-
-
Hyōgo
-
Akashi, Hyōgo, Giappone, 673-8558
- Hyogo Cancer Center ( Site 4195)
-
-
Iwate
-
Shiwa-gun, Iwate, Giappone, 028-3695
- Iwate Medical University Hospital ( Site 4189)
-
-
Okinawa
-
Ginowan, Okinawa, Giappone, 901-2725
- University of the Ryukyus Hospital ( Site 4184)
-
-
Saitama
-
Hidaka, Saitama, Giappone, 350-1298
- Saitama Medical University International Medical Center ( Site 4182)
-
-
Shizuoka
-
Suntogun, Shizuoka, Giappone, 411-8777
- Shizuoka Cancer Center ( Site 4192)
-
-
-
-
-
Thessaloniki, Grecia, 546 45
- Euromedica General Clinic of Thessaloniki ( Site 2422)
-
-
Achaia
-
Pátrai, Achaia, Grecia, 263 35
- General Hospital of Patras. St Andrews ( Site 2421)
-
-
Attica
-
Athens, Attica, Grecia, 115 28
- Geniko Panepistimako Nosokomeio ARETEIO ( Site 2423)
-
Athens, Attica, Grecia, 115 28
- Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)
-
Chaïdári, Attica, Grecia, 124 62
- Athens University Hospital ATTIKON ( Site 2424)
-
Marousi, Attica, Grecia, 151 23
- Hospital Hygeia ( Site 2426)
-
-
-
-
-
Haifa, Israele, 3525408
- Rambam Medical Center ( Site 2307)
-
Holon, Israele, 5810001
- Edith Wolfson Medical Center ( Site 2306)
-
Jerusalem, Israele, 9112001
- Hadassah Medical Center. Ein Kerem ( Site 2303)
-
Petah Tikva, Israele, 4941492
- Rabin Medical Center ( Site 2305)
-
Ramat Gan, Israele, 5265601
- Chaim Sheba Medical Center ( Site 2301)
-
-
-
-
-
Brescia, Italia, 25123
- Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)
-
Milan, Italia, 20132
- IRCCS Ospedale San Raffaele ( Site 2130)
-
Milan, Italia, 20141
- Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 2132)
-
Naples, Italia, 80131
- Azienda Ospedaliera Universitaria Federico II ( Site 2123)
-
Naples, Italia, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)
-
Padova, Italia, 35128
- Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 2134)
-
-
Abruzzo
-
Roma, Abruzzo, Italia, 00144
- Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)
-
-
Lazio
-
Rome, Lazio, Italia, 00168
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)
-
-
Piedmont
-
Candiolo, Piedmont, Italia, 10060
- INOC - Istituto Nazionale Oncologico Candiolo ( Site 2125)
-
-
-
-
-
Mexico City, Messico, 06700
- Hospital Angeles Roma ( Site 1123)
-
-
Baja California Sur
-
La Paz, Baja California Sur, Messico, 23040
- Investigacion Onco Farmaceutica S de RL de CV ( Site 1127)
-
-
Chiapas
-
Tuxtla Gutiérrez, Chiapas, Messico, 29090
- Hospital San Lucas Cardiologica del Sureste ( Site 1122)
-
-
Mexico City
-
Mexico City, Mexico City, Messico, 04700
- Centro Oncologico Internacional. SEDNA ( Site 1121)
-
Mexico City, Mexico City, Messico, 14080
- Instituto Nacional de Cancerologia ( Site 1124)
-
-
Nuevo León
-
Monterrey, Nuevo León, Messico, 64460
- Filios Alta Medicina ( Site 1125)
-
Monterrey, Nuevo León, Messico, 64710
- I Can Oncology Center SA de CV ( Site 1126)
-
-
-
-
-
Oslo, Norvegia, 0310
- Oslo Universitetssykehus Radiumhospitalet ( Site 2151)
-
-
Troms
-
Tromsø, Troms, Norvegia, 9019
- University Hospital of North Norway ( Site 2153)
-
-
Vest-Agder
-
Kristiansand, Vest-Agder, Norvegia, 4615
- Soerlandet sykehus HF Kristiansand ( Site 2152)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polonia, 61-866
- Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polonia, 08-110
- Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2487)
-
Warsaw, Masovian Voivodeship, Polonia, 00-315
- Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polonia, 15-027
- Bialostockie Centrum Onkologii ( Site 2483)
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polonia, 44-102
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, Polonia, 10-228
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2486)
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polonia, 25-734
- Swietokrzyskie Centrum Onkologii. ( Site 2485)
-
-
-
-
-
Leicester, Regno Unito, LE1 5WW
- Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 2249)
-
Manchester, Regno Unito, M20 4BX
- The Christie Hospital NHS Foundation Trust ( Site 2243)
-
-
Bristol, City of
-
Bristol, Bristol, City of, Regno Unito, BS2 8ED
- Bristol Haematology and Oncology Centre ( Site 2244)
-
-
East Riding Of Yorkshire
-
Cottingham, East Riding Of Yorkshire, Regno Unito, HU165JQ
- Castle Hill Hospital-Academic Oncology ( Site 2252)
-
-
Glasgow City
-
Glasgow, Glasgow City, Regno Unito, G12 0YN
- Beatson West of Scotland Cancer Centre ( Site 2247)
-
-
London, City of
-
London, London, City of, Regno Unito, NW1 2PG
- UCLH NHS Foundation Trust ( Site 2242)
-
London, London, City of, Regno Unito, SW3 6JJ
- Royal Marsden NHS Foundation Trust ( Site 2248)
-
Sutton, London, City of, Regno Unito, SM2 5PT
- Royal Marsden Hospital Sutton-Surrey ( Site 2241)
-
-
-
-
Arkhangelskaya oblast
-
Arkhangelsk, Arkhangelskaya oblast, Russia, 163045
- Arkhangelsk Clinical Oncological Dispensary ( Site 2637)
-
-
Baskortostan, Respublika
-
Ufa, Baskortostan, Respublika, Russia, 450054
- Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)
-
-
Chelyabinsk Oblast
-
Chelyabinsk, Chelyabinsk Oblast, Russia, 454087
- Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
-
-
Krasnoyarsk Krai
-
Krasnoyarsk, Krasnoyarsk Krai, Russia, 660133
- Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)
-
-
Mordoviya, Respublika
-
Saransk, Mordoviya, Respublika, Russia, 430032
- National Research Ogarev Mordovia State University ( Site 2648)
-
-
Moscow
-
Moscow, Moscow, Russia, 115522
- Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF Dep.of antitumor drug therapy #4 ( Site 2634)
-
Moscow, Moscow, Russia, 125284
- Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2631)
-
-
Nizhny Novgorod Oblast
-
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia, 603126
- Scientific Research Institute of Clinical Oncology "Nizhegorodsky Regional Oncology Dospensary" ( Site 2639)
-
-
Samara Oblast
-
Samara, Samara Oblast, Russia, 443031
- Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Russia, 197758
- Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)
-
-
Tatarstan, Respublika
-
Kazan', Tatarstan, Respublika, Russia, 420029
- Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2646)
-
-
Tomsk Oblast
-
Tomsk, Tomsk Oblast, Russia, 634028
- Tomsk Scientific Research Institute of Oncology-Chemotherapy ( Site 2638)
-
-
Yaroslavl Oblast
-
Yaroslavl, Yaroslavl Oblast, Russia, 150054
- Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)
-
-
-
-
-
Barcelona, Spagna, 08035
- Hospital Vall D Hebron ( Site 2182)
-
Barcelona, Spagna, 08036
- Hospital Clinic i Provincial ( Site 2185)
-
Córdoba, Spagna, 14004
- Hospital Universitario Reina Sofia ( Site 2183)
-
Madrid, Spagna, 28040
- Hospital Clinico San Carlos ( Site 2187)
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz ( Site 2186)
-
-
Gerona
-
Girona, Gerona, Spagna, 17007
- Institut Català d'Oncologia (ICO) - Girona ( Site 2184)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spagna, 28027
- Clinica Universitaria de Navarra ( Site 2181)
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35249
- University of Alabama - Birmingham ( Site 3061)
-
Mobile, Alabama, Stati Uniti, 36604
- University of South Alabama, Mitchell Cancer Institute ( Site 3058)
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85016
- HonorHealth Research Institute - Biltmore ( Site 3043)
-
Tucson, Arizona, Stati Uniti, 85711
- Arizona Oncology Associates PC- HOPE ( Site 3049)
-
-
California
-
La Jolla, California, Stati Uniti, 92093-0698
- UCSD Moores Cancer Center ( Site 3053)
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University Of Colorado ( Site 3051)
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06511
- Smilow Cancer Hospital at Yale New Haven ( Site 3070)
-
-
Florida
-
Miami Beach, Florida, Stati Uniti, 33140
- Mount Sinai Cancer Center ( Site 3081)
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30342
- Northside Hospital ( Site 3036)
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern Memorial Hospital ( Site 3044)
-
-
Indiana
-
Fort Wayne, Indiana, Stati Uniti, 46845
- Parkview Cancer Institute ( Site 3067)
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa Hospital and Clinics ( Site 3046)
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40207
- Norton Cancer Institute - St. Matthews ( Site 3056)
-
-
Louisiana
-
Shreveport, Louisiana, Stati Uniti, 71103
- WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
-
-
Massachusetts
-
Worcester, Massachusetts, Stati Uniti, 01605
- University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
-
-
New York
-
Mineola, New York, Stati Uniti, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
-
New York, New York, Stati Uniti, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center ( Site 3065)
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke Cancer Center ( Site 3072)
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58102
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Good Samaritan Medical Center ( Site 3033)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- AHN West Penn Hospital ( Site 3060)
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Abington Hospital - Asplundh Cancer Center ( Site 3073)
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Gynecology Oncology ( Site 3045)
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern Medical Center ( Site 3063)
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Cancer Center ( Site 3068)
-
-
-
-
Stockholm County
-
Solna, Stockholm County, Svezia, 171 76
- Karolinska Universitetssjukhuset Solna ( Site 2220)
-
-
Uppsala County
-
Uppsala, Uppsala County, Svezia, 751 85
- Blod-och Tumorsjukdomar ( Site 2221)
-
-
Östergötland County
-
Linköping, Östergötland County, Svezia, 581 85
- Universitetssjukhuset i Linkoping. ( Site 2222)
-
-
-
-
-
Changhua, Taiwan, 50006
- Changhua Christian Hospital ( Site 4095)
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital ( Site 4094)
-
Taipei, Taiwan, 10449
- MacKay Memorial Hospital ( Site 4092)
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital ( Site 4093)
-
Taoyuan, Taiwan, 33305
- Linkou Chang Gung Memorial Hospital ( Site 4091)
-
-
-
-
-
Adana, Turchia (Türkiye), 01250
- Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)
-
Adana, Turchia (Türkiye), 01330
- Cukurova Uni. Tip Fakultesi ( Site 2353)
-
Ankara, Turchia (Türkiye), 06490
- Baskent Universitesi Ankara Hastanesi ( Site 2354)
-
Ankara, Turchia (Türkiye), 06590
- Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)
-
Istanbul, Turchia (Türkiye), 34214
- Medipol Universite Hastanesi ( Site 2352)
-
Izmir, Turchia (Türkiye), 35100
- Ege University Medical Faculty ( Site 2351)
-
Izmir, Turchia (Türkiye), 35575
- I.E.U. Medical Point Hastanesi ( Site 2356)
-
-
-
-
Chernihiv Oblast
-
Chernihiv, Chernihiv Oblast, Ucraina, 14029
- Chernihiv Medical Center of Modern Oncology ( Site 2368)
-
-
Chernivetska Oblast
-
Chernivtsi, Chernivetska Oblast, Ucraina, 58013
- Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 2366)
-
-
Kharkiv Oblast
-
Kharkiv, Kharkiv Oblast, Ucraina, 61024
- SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)
-
-
Khmelnytskyi Oblast
-
Khmelnitskyi, Khmelnytskyi Oblast, Ucraina, 29009
- MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
-
-
Kyivska Oblast
-
Kiev, Kyivska Oblast, Ucraina, 08720
- LISOD - Israeli Oncological Hospital MedX-ray International Group LLC ( Site 2364)
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ucraina, 79031
- Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2361)
-
-
Volyn Oblast
-
Lutsk, Volyn Oblast, Ucraina, 43018
- Volyn Regional Clinical Hospital Regional Medical Oncology Centre ( Site 2362)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor) and:
- Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy; and
- Is at high risk for recurrence following treatment with curative intent surgery, ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009 surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO 2009 surgical stage I/II with myometrial invasion of any histology with known aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA of any histology.
-
Is disease-free with no evidence of loco-regional disease or distant metastasis post operatively and on imaging.
-
Has not received any radiation or systemic therapy, including immunotherapy, hormonal therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting including the neoadjuvant setting for endometrial cancer (EC).
-
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
-
Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or Carcinosarcoma for prospective determination of histology and mismatch repair (MMR) status by central vendor is required for all participants.
-
Has adequate organ function within 7 days of randomization.
Exclusion Criteria:
-
Has recurrent endometrial carcinoma or carcinosarcoma.
-
Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.
-
Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known aberrant p53 expression or p53 mutation.
-
Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A (POLE) mutation.
-
Has FIGO Stage IVB disease of any histology even if there is no evidence of disease after surgery.
-
Has residual tumor whether measurable or non-measurable after surgery.
-
Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
- Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
-
Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
-
Has received a live vaccine within 30 days before the first dose of study intervention.
- Note: killed vaccines are allowed.
-
Has a known intolerance to study intervention (or any of the excipients).
-
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
- Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
-
Has any contraindication to the use of carboplatin or paclitaxel.
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
-
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
-
Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
-
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
-
Has an active infection requiring systemic therapy.
-
Has a known history of HIV infection.
-
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
-
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
-
Has had an allogenic tissue/solid organ transplant.
-
Has not recovered adequately from surgery and/or any complications from the surgery.
-
Is breastfeeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Pembrolizumab + Chemotherapy
Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion
Altri nomi:
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Altri nomi:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Altri nomi:
Given according to local practice, at the discretion of the investigator
Altri nomi:
|
|
Comparatore placebo: Placebo + Chemotherapy
Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Altri nomi:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Altri nomi:
Given according to local practice, at the discretion of the investigator
Altri nomi:
IV infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
Lasso di tempo: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS)
Lasso di tempo: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 54 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence
Lasso di tempo: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Lasso di tempo: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Lasso di tempo: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 54 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Lasso di tempo: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Lasso di tempo: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Lasso di tempo: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Lasso di tempo: Up to approximately 52 weeks
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 52 weeks
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score
Lasso di tempo: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 ("How would you rate your overall health during the past week?") and 30 ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score
Lasso di tempo: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score
Lasso di tempo: Baseline and up to approximately 54 months
|
The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented. |
Baseline and up to approximately 54 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC
Pubblicazioni e link utili
Pubblicazioni generali
- Van Gorp T, Cibula D, Lv W, Backes F, Ortac F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B; ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024 Nov;35(11):968-980. doi: 10.1016/j.annonc.2024.08.2242. Epub 2024 Sep 14.
- Slomovitz BM, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Danska-Bidzinska A, Samouelian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, Willmott LJ, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T. Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. J Clin Oncol. 2025 Jan 20;43(3):251-259. doi: 10.1200/JCO-24-01887. Epub 2024 Oct 16.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie genitali, femmina
- Neoplasie uterine
- Neoplasie endometriali
- Malattia di Parkinson 4, corpo di Lewy autosomico dominante
- Prodotti chimici organici
- Terapie
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Composti di platino
- Radioterapia
- Docetaxel
- Carboplatino
- Paclitaxel
- Cisplatino
- pembrolizumab
- Brachiterapia
Altri numeri di identificazione dello studio
- 3475-B21
- KEYNOTE-B21 (Altro identificatore: MSD)
- ENGOT-en11 (Altro identificatore: European Network for Gynaecological Oncological Trial groups)
- GOG-3053 (Altro identificatore: Gynecologic Oncology Group)
- jRCT2031200399 (Identificatore di registro: jRCT)
- 2020-003424-17 (Numero EudraCT)
- 2022-501973-37-00 (Identificatore di registro: EU CT)
- U1111-1282-6430 (Identificatore di registro: UTN)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .